Gilead prices Covid-19 drug candidate Remdesivir at US$2,340 per patient

Gilead Sciences Inc has priced its Covid-19 drug candidate Remdesivir at US$2,340 for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at US$390.

The price for US private insurance companies will be US$520 per vial, the drugmaker said, which equates to US$3,120 per patient for a treatment course using six vials of Remdesivir.